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ABSTRACT
Genomic instability and epigenetic aberrations are important classifiers of human 
tumors, yet, their interrelations are poorly understood. We used Lynch syndrome 
(LS) to address such relationships. Forty-five tumors (11 colorectal adenomas, 18 
colorectal carcinomas, and 16 ovarian carcinomas) were profiled for CpG Island 
Methylator Phenotype (CIMP) and somatic mutations. All tumors showed high-degree 
microsatellite instability. Panel sequencing of 578 cancer-relevant genes revealed 
the average number of 1433, 1124, and 657 non-synonymous somatic mutations per 
colorectal adenoma, colorectal carcinoma, and ovarian carcinoma, respectively. Genes 
harboring mutations with allele frequency 25 % or higher in at least 31 % of tumors 
were regarded to be possible drivers. Among 72 and 10 such genes identified in 
colorectal and ovarian tumors, respectively, the most frequently mutated genes BRD4 
and MLL2 (62 % of colorectal tumors) and ARID1A (50 % of ovarian carcinomas) are 
involved in epigenetic regulation. The total number of somatic mutations or mutant 
genes per tumor were significantly associated with CIMP. Our results suggest that 
even in an inherited disease, tumor type-specific epigenetic changes are significant 
and may result from regulatory changes (CIMP) or structural events (mutations of 
epigenetic regulatory genes). The findings are clinically relevant since many of the 
affected pathways can be therapeutically targeted.
INTRODUCTION
Genomic instability and epigenetic aberrations 
divide human tumors into biologically and clinically 
meaningful subgroups. Large-scale sequencing studies 
show that 16 % of colorectal carcinomas are hypermutated 
and most of these exhibit high-degree microsatellite 
instability (MSI-H) [1]. In sporadic tumors, biallelic MLH1 
promoter methylation as part of a generalized CpG island 
methylator phenotype (CIMP) is the main mechanism 
behind MSI-H. Similarly, genomic and epigenomic 
profiling classifies epithelial ovarian carcinomas [2] and 
endometrial carcinomas [3] into separate subgroups with 
distinct behavior and different requirements for clinical 
management. Current evidence supports the existence of 
pan-cancer CIMP [4]. However, a universal, causal set of 
mutations driving CIMP is yet to be identified.
Lynch syndrome (LS) is a well-established cancer 
predisposition syndrome with an increased risk of 
colorectal, endometrial, ovarian, and other malignancies 
resulting from germline mutations in DNA mismatch 
repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 [5]. 
Contrary to sporadic MSI-H tumors, two-hit inactivation 
in microsatellite-unstable LS tumors occurs by a genetic 
mechanism, typically loss of heterozygosity (LOH) [6]. 
The patterns of CIMP in tumor tissues from LS patients 
overlap with those of the corresponding sporadic tumors 
[6]. LS tumors may also exhibit distinct profiles of somatic 
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mutations and epigenetic aberrations; for example, we 
have described a unique molecular profile for ovarian 
carcinomas in LS, possibly explaining the surprisingly 
favorable outcome of LS-associated disease [7].
Our recent investigation showed that DNA 
hypermethylation accompanies increasing dysplasia in 
LS-associated colorectal tumorigenesis [8]. To gain insight 
into the interplay between genetic and epigenetic events, 
which is poorly understood at present, we now set out to 
determine the somatic mutation profiles of 29 colorectal 
tumors from the same series by targeted sequencing. To 
address the question of tumor-type specificity of acquired 
molecular changes in this multiorgan cancer syndrome 
where the predisposing mutation is present in every cell, 
16 ovarian carcinomas from LS mutation carriers were 
examined for comparison. Our findings reveal organ-
specific patterns of mutant genes and a close connection 
between hypermutability and CIMP.
RESULTS
Mechanisms of MMR gene inactivation
Among 11 colorectal adenomas, 18 colorectal 
carcinomas, and 16 ovarian carcinomas examined from 
MMR gene mutation carriers, all showed high-degree 
MSI (Table 1). The first (germline) and second (somatic) 
hits are shown case by case in Supplementary Table 1 and 
summarized in Table 2. LOH, somatic point mutations, 
and promoter methylation were addressed as possible 
second hits. Loss of the wild-type allele of the MMR 
gene involved was the most common second hit, being 
particularly frequent in colorectal adenomas (9/11, 82 %), 
but also in those colorectal carcinomas (9/17, 53 %) and 
ovarian carcinomas (7/11, 64 %) that could be assessed for 
second hits. Somatic point mutations in the predisposing 
MMR genes provided obvious second hits for most 
cases without LOH. MLH1 was our particular focus in 
methylation analyses; no increased methylation in tumor 
tissue was detected in any MLH1-associated cases.
Profiles of somatic mutations stratified by CIMP
The average number of nonsynonymous somatic 
mutations was 1442, 1124, and 657 per colorectal 
adenoma, colorectal carcinoma, and ovarian carcinoma, 
respectively (Table 3). All colorectal adenomas had 
high-grade dysplasia and were combined with colorectal 
carcinomas in further analyses. The mean number of 
somatic mutations in colorectal tumors (1245) was 
significantly higher compared to ovarian carcinomas (P = 
0.0004). The average number of mutant genes out of 578 
examined is given in two ways in Table 3, using a mutant 
allele frequency of 25 % as a divider between high and 
low-frequency mutations [9]. The mean number of genes 
with nonsynonymous high-frequency mutations was 2.9-, 
1.5-, and 2.3-fold higher in CIMP positive than CIMP 
negative colorectal adenomas colorectal carcinomas, and 
ovarian carcinomas, respectively (in ovarian carcinomas, 
the difference was evident even without restriction to high-
frequency mutations). When colorectal and ovarian tumors 
were combined, the difference between CIMP positive 
and CIMP negative tumors was statistically significant 
irrespective of the somatic mutation parameter (number 
of somatic mutations or mutant genes) used (Table 3). To 
demonstrate that the result did not depend on any specific 
system of CIMP classification, we additionally examined 
our colorectal tumors with the same MS-MLPA assay 
used for ovarian tumors (see Materials and Methods) 
and performed correlation analysis on the combined set 
of tumors by treating methylation status as a continuous 
variable (Supplementary Table 2). The number of 
methylated genes out of 24 showed a significant positive 
correlation with the number of mutant genes in the same 
tumors (p = 0.002 considering any mutant allele frequency 
and p = 0.006 if only genes affected with high-frequency 
mutations were taken into account). Collectively, our 
results indicated that CIMP status significantly influenced 
the tendency to acquire somatic mutations.
Genes characteristic of colorectal vs. ovarian 
tumorigenesis
The proportion of tumors in which a particular 
gene was mutant was calculated for each of the 578 genes 
(Supplementary Table 3). Focusing on mutations with high 
allele frequencies (> 25 %), 51 genes showed no mutations 
in colorectal tumors, whereas the other extreme of the 
distribution consisted of 2 genes mutant in 18 tumors. For 
ovarian tumors, the distribution of mutant genes ranged 
from 285 genes showing no high-frequency mutations to 
1 gene mutant in 8 tumors. The distribution of mutated 
genes in colorectal tumors suggested that 9/29 mutant 
tumors (31 %) provided a cut-off that divided the tumors 
into commonly and less commonly mutated ones. The 
same threshold (5/16, 31 %) was subsequently applied 
to ovarian carcinomas to allow for tumor type-specific 
comparisons. Using the tumor proportion of 31 % and 
mutant allele frequency of 25 % or higher as requirements, 
72 genes characteristic of colorectal tumorigenesis (Figure 
1) and 10 genes characteristic of ovarian tumorigenesis 
(Figure 2) were identified. Pathway annotation of each 
gene is given in Supplementary Table 4. Twenty-nine 
of the 72 colon tumor-associated genes including, e.g., 
the Wnt-signaling-pathway genes APC, TCF7L2, and 
FAM123B showed significant specificity for colorectal 
tumors (Figure 1 and Supplementary Table 4). Likewise, 
a majority of the 10 ovarian carcinoma-associated genes 
were preferentially affected in ovarian carcinoma (Figure 
2), although the differences did not reach statistical 
significance (borderline significant difference for PIK3CA, 
Supplementary Table 4). The ARID1A, BCR, CHD5, 
Oncotarget108022www.impactjournals.com/oncotarget
RPL22 and TSC2 genes were shared mutation targets 
in ovarian and colorectal carcinomas. RPL22 contains a 
coding repeat which makes it mutation-prone in tumors 
with MSI [10, 11].
Genes with a primary function in epigenetic 
regulation comprised 8 % (47/578) of all genes 
interrogated in the Comprehensive Cancer Panel. They 
were significantly enriched among our designated 
colorectal tumor-associated genes (15/72, 21 %, p = 
0.0015 by two-tailed Fisher’s test) and ovarian carcinoma-
associated genes (3/10, 30 %, p = 0.045) (Figures 1 and 
2). For comparison, DNA repair genes were not at all 
enriched (these accounted for 4/72, 6 %, of colon tumor-
associated genes and 0 % of ovarian tumor-associated 
genes, whereas the entire panel included 47 such genes, 
8 %). The detailed patterns of involvement of all 47 
epigenetic key genes examined are shown for each 
tumor in Figure 3. With a few exceptions, inactivation 
(loss of function) is expected to underlie pathogenicity 
of epigenetic regulatory genes [12–14]. A significant 
fraction of somatic mutations observed in epigenetic 
regulatory genes in our investigation were truncating 
frameshift or nonsense mutations compatible with loss of 
function (Figure 3, Supplementary Table 5, Supplementary 
Figure 1). In addition, a notable proportion of missense 
mutations may be pathogenic based on in silico predictions 
(Supplementary Table 5). Some mutations were recurrent, 
since they had previously been deposited to the COSMIC 
database (Supplementary Table 5).
Table 1: Characteristics of LS sample series
Predisposing gene MMR status CIMP status*




22 (76 %) 3 (10 %) 4 (14 %) 29 (100 %) 0 18 (62 %) 11 (38 %) 0
Adenoma 
(n = 11) 10 (91 %) 1 (9 %) 0 11 (100 %) 0 9 (82 %) 2 (18 %) 0
Carcinoma 




13 (81 %) 3 (19 %) 0 16 (100 %) 0 12 (75 %) 3 (19 %) 1 (6 %)
Total (n = 
45) 35 (78 %9 6 (13 %) 4 (9 %) 45 (100 %) 0 30 (67 %) 14 (31 %) 1 (2 %)
*Determined by MS-MLPA (ME042-B2 for colorectal tumors and ME001-C1 for ovarian carcinomas; see Materials and 
Methods).
ND, could not be determined due to shortage of DNA.





+ somatic point 
mutation No obvious second hit ND
Colorectal adenoma (n = 11) 9 2 0 0
Colorectal carcinoma (n = 18) 9 6 2 1
Ovarian carcinoma (n = 16) 7 3 1 5
Mutations that had the possibility of being pathogenic (pathogenic, likely pathogenic, or pathogenicity unknown) were 




DNA MMR deficiency is known to underlie MSI 
and hypermutability in LS and sporadic tumors, but 
the mutational landscapes may differ depending on the 
mechanism of MMR gene inactivation [7, 15]. Even in LS 
mutation carriers, MSI is not invariably present but shows 
tumor type-specific variation, likely reflecting different 
patterns of clonal growth [6]. Of the tumor spectrum in 
LS, colorectal and ovarian tumors are associated with 
MSI-H as a rule. The CIMP patterns likewise display 
tumor type-specific variation in LS, clearly distinguishing 
gastrointestinal from gynecological tumors [6]. These 
aspects made us reason that colorectal and ovarian 
tumors from LS individuals would provide an informative 
comparative setting to investigate the relationship between 
somatic mutations and epigenetic aberrations against a 
shared pattern of MSI-H.
A comprehensive evaluation of the mechanisms of 
two-hit inactivation identified loss of the wild-type allele 
as the predominant mechanism of the second hit in both 
colorectal and ovarian tumors (Table 2). Previous reports 
are available from LS colorectal tumors [16, 17] with 
findings that comply with our results. Among tumors 
without LOH, parallel sequencing detected a somatic 
point mutation as the likely second hit in most cases. 
Interestingly, somatic mutations of the predisposing MMR 
genes were relatively common also in tumors where wild-
type allele loss already provided the necessary second 
hit (Supplementary Table 1). This suggests that multiple 
clones with different second hits were likely to occur in 
a single tumor, in agreement with observations of clonal 
heterogeneity inferred from patterns of microsatellite 
repeats [18].
The so called neutral evolution with clonal selection 
occurring before the onset of cancer growth has been 
Table 3: Average numbers of somatic non-synonymous mutations and mutant genes among 578 cancer-relevant 
genes investigated





Average no. of 





Average no. of mutant 
genes (frequency ≥ 25 
% for mutant alleles) p-value
Colorectal adenoma 
(n = 11) 1442 370 78
CIMP-negative (n = 9) 1433 ns 355 ns 58 ns (0.099)
CIMP-positive (n = 2) 1485 440 170
Colorectal carcinoma 
(n = 18) 1124 361 97
CIMP-negative (n = 9) 1050 ns 346 ns 77 ns
CIMP-positive (n = 9) 1198 375 118
Colorectal tumors 
combined (n = 29) 1245 364 90
CIMP-negative (n = 18) 1242 ns 351 ns 67 ns (0.076)
CIMP-positive (n = 11) 1250 387 128
Ovarian carcinoma (n 
= 16)* 657 162 30
CIMP-negative (n = 12) 252 0.014 99 0.014 25 0.030
CIMP-positive (n = 3) 2494 464 58
Colorectal and 
ovarian tumors 
combined (n = 45) *
954 287 70
CIMP-negative (n = 30) 846 0.011 250 0.019 50 0.004
CIMP-positive (n = 14) 1517 403 113
*Includes one ovarian carcinoma with CIMP status unknown. 
p-values were calculated by Mann-Whitney U test (ns, non-significant). 
Case-by-case data on CIMP status vs. no. of mutations or mutant genes are shown in Supplementary Table 2.
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proposed as a mechanism of intratumoral heterogeneity 
[9]. Based on Williams et al. [9], we focused on mutations 
with allele frequency 25 % or higher to increase the 
likelihood of clonal (driver) as opposed to subclonal 
(passenger) mutations. When involvement in at least 
31% of tumors was set as an additional requirement, 72 
potential driver genes were identified among colorectal 
tumors (Figure 1) and 10 among ovarian carcinomas 
(Figure 2). These gene sets had two cardinal features. 
First, signature genes characteristic of the tumor types 
in question, such as APC in colorectal tumors [1] and 
ARID1A, PIK3CA, and PTEN in non-serous ovarian 
carcinomas [19, 20] were well represented. Second, genes 
responsible for epigenetic regulation were significantly 
enriched.
BRD4 encoding a chromatin remodeler and MLL2 
encoding a H3K4 methyltransferase were the top mutant 
genes in colorectal tumors (62 %) and ARID1A, a 
chromatin remodeler gene, in ovarian carcinomas (50 %). 
Chromatin remodelers are often affected by inactivating 
mutations in human cancers, which can result in altered 
expression of their target genes [21]. However, the 
occurrence of mutations in BRD4 specifically has been 
reported to be low in cancers [22]. Our data revealed 
high-frequency mutations in BRD4 or BRD3 or both 
(Figure 1) in 79 % (23/29) of colorectal tumors, which 
is, therefore, a novel finding. Interestingly, BRD4 can 
act in a tumor-promoting or tumor-protective manner 
depending on the type of tumors [22]. In colorectal cancer 
it is mainly tumor-protective [22], which is consistent with 
our observation of frequent loss-of-function mutations 
Figure 1: Colorectal tumor-associated genes. Genes affected with high-frequency mutations (mutant allele frequency > 25 %) 
in at least 31 % (9/29) of LS-colorectal tumors are shown. Mutation percentages of the same 72 genes in LS-ovarian carcinomas are 
displayed for comparison. Epigenetic regulatory genes are marked with an asterisk and DNA repair genes with an arrowhead (please see 
Supplementary Table 4 for functional annotation of the remaining genes).
Figure 2: Ovarian carcinoma-associated genes. Genes affected with high-frequency mutations (mutant allele frequency > 25 %) in 
at least 31 % (5/16) of LS-ovarian carcinomas are shown. Mutation percentages of the same 10 genes in LS-colorectal tumors are displayed 
for comparison. Epigenetic regulatory genes are marked with an asterisk.
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affecting this gene (Figure 3 and Supplementary Table 5). 
MLL2 is a known mutational target gene in (MSI) colon 
cancer [23] and according to recent findings may drive 
tumorigenesis through genome instability and increased 
gene mutations [24].
A key finding of our investigation was that the 
total number of somatic mutations, or mutant genes per 
tumor, were significantly associated with CIMP. The cause 
and consequence relationships are unknown. In theory, 
mutations in genes with epigenetic regulatory function 
could lead to CIMP. Tahara et al. [25] discovered that 
somatic mutations in chromatin regulator genes CHD7 
and CHD8 (neither was included in our targeted gene 
panel) were enriched in sporadic colorectal carcinomas 
with CIMP and MSI due to MLH1 promoter methylation 
(the CIMP1 subgroup). Genes frequently methylated in 
CIMP positive tumors were increasingly bound by CHD7 
supporting the idea that CHD7 mutations contributed to 
CIMP. Conversely, CIMP might induce somatic mutations. 
Deamination of 5-methylcytosine at CpG dinucleotides 
is a known mechanism of C to T transitions [26], the 
predominant SNV type in MSI colorectal cancers [10]. 
Many repair genes (including MLH1) could be affected 
by promoter methylation as part of CIMP [27], with 
increased overall mutation frequencies in tumors as a 
possible consequence. In the study by Tahara et al. [25], 
CIMP1 colorectal carcinomas had a higher total frequency 
of somatic mutations compared to CIMP1 colorectal 
adenomas or non-CIMP colorectal carcinomas (MSS). 
A possibility remained that the higher mutation rate in 
CIMP1 colorectal carcinomas primarily reflected their 
MMR deficiency. In our investigation, MMR status was 
not a possible confounding factor since it was similar 
(MSI-H) in CIMP positive and CIMP negative tumors. 
Contrary to Tahara et al. [25], we saw no difference 
between colorectal adenomas and carcinomas (Table 3), 
which was possibly due to the different settings (sporadic 
and LS, respectively).
Our findings are clinically relevant. Apart from 
epigenetic regulation, many other central biological 
pathways (such as DNA repair, Wnt, mTOR, PI3K, 
NOTCH, MAPK, and tyrosine kinase signaling) are 
represented among the top mutant genes we identified 
(Figures 1 and 2, and Supplementary Table 4). Several 
of these pathways can be therapeutically targeted [28, 
29]. A recent study found that ERBB2-mutant MSI 
colorectal cancer was susceptible to irreversible pan-HER 
inhibitors [30]. The ERBB2 mutation rate (15 %) in their 
series fulfilling Bethesda or Amsterdam II criteria was 
comparable to our LS colorectal tumors with 5/29 (17 %) 
Figure 3: Somatic mutation patterns of all 47 epigenetic key genes included in the Comprehensive Cancer Panel. The 
codes for mutation classification are 0 (white), not mutant; 1 (light red), one or more mutations (truncating or non-truncating) with variant 
allele frequency < 25 % in tumor tissue; 2 (medium red), one or more non-truncating mutations with variant allele frequency ≥ 25 % in 
tumor tissue; 3 (dark red), one or more truncating mutations with variant allele frequency ≥ 25 % in tumor tissue.
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showing high-frequency mutations. Finally, the general 
tendency of MMR-deficient tumors to accumulate somatic 
mutations makes them good candidates for checkpoint 
blockade-based immunotherapy [31].
Taken together, the causes of CIMP remain 
elusive and the consequences of this phenomenon are 
incompletely understood. Our targeted sequencing 
experiments on LS mutation carriers showed that 
colorectal and ovarian tumors with CIMP tended to 
accumulate somatic mutations and mutant cancer-relevant 
genes, especially those associated with high mutant allele 
frequencies characteristic of driver genes. Epigenetic 
regulatory genes were significantly enriched among 
mutant genes. These findings are interesting and novel 
and encourage further research. Additional investigations 
are necessary to address in detail the complex questions 
regarding the cause and effect relationships. The genes 
we report mutant are common cancer genes with most 
listed in the Cancer Gene Census (Supplementary Table 
4). Therefore, future research should also be directed to 
establish the extent to which the associations we found 
between somatic mutations and CIMP in LS tumors can 
be recapitulated in the sporadic setting.
MATERIALS AND METHODS
Patients and samples
This study included 45 tumor specimens and their 
corresponding normal samples from 39 LS mutation 
carriers from the Hereditary Colorectal Cancer Registry 
of Finland (Table 1). Ovarian carcinomas were all non-
serous (13 endometrioid and 3 clear cell) as typical of LS 
[7]. All tumors and eight normal samples were formalin-
fixed paraffin embedded (FFPE) specimens, whereas the 
remaining normal samples were blood specimens. The 
average tumor percentage was 46 %, 47 %, and 67 % in 
colorectal adenoma, colorectal carcinoma and ovarian 
carcinoma, respectively (Supplementary Table 2). DNA 
was isolated using non-enzymatic protocols according 
to Isola et al. [32], and Lahiri and Nurnberger [33] for 
FFPE and blood specimens, respectively. The Institutional 
Review Boards of the Helsinki University Central Hospital 
(466/E6/01) and Central Finland Health Care District 
(10U/2011) approved this study. The National Supervisory 
Authority for Welfare and Health (Dnro 1272/04/044/07 
and Dnro 10741/06.01.03.01/2015) approved the 
collection of archival specimens.
Microsatellite instability (MSI) analysis
MSI status was determined using mononucleotide 
repeat markers BAT25 and BAT26 that are specific and 
sensitive indicators of high-degree MSI (MSI-H) [34, 35].
CpG island methylator phenotype (CIMP) status
Colorectal tumors were investigated by methylation-
specific multiplex ligation-dependent probe amplification 
(MS-MLPA) using SALSA MS-MLPA probemix 
ME042-B2 (MRC Holland, Amsterdam, The Netherlands 
(http://mrc-holland.com) as described [8]). Samples were 
classified CIMP positive when at least 3 of 5 genes from 
the Weisenberger et al. [36] panel (CACNA1G, IGF2, 
NEUROG1, RUNX3, and SOCS1) were methylated. For 
ovariantumors, no established CIMP criteria exist, and 
the corresponding methylator phenotype was determined 
using SALSA MS-MLPA probemix ME001-C1 (MRC 
Holland, Amsterdam, The Netherlands) for 24 tumor 
suppressor genes as described [7]. According to our 
previous experience [37], a tumor was considered CIMP 
positive when 5 or more genes were methylated.
Panel sequencing
Sequencing was conducted at the Institute for 
Molecular Medicine Finland (FIMM; Helsinki, Finland) 
using the Nimblegen Comprehensive Cancer Panel (Roche 
Diagnostics), a 4Mb design with 578 cancer-related genes 
compiled from the Sanger Institute Cancer Gene Census 
Database and the NCBI Gene tests databases. Libraries 
were prepared using ThruPLEX® DNA-seq Kit, and the 
exons captured according to the manufacturer’s protocol 
(Rubicon Genomics). Sequencing was performed on 
Illumina HiSeq 2500 platform (San Diego, CA). The mean 
target coverage was 41-fold for colorectal and 72-fold for 
ovarian tumors (Supplementary Table 6).
The pipeline used for variant calling is described in 
Sulonen et al. [38] Raw Illumina reads were first merged 
with SeqPrep. Resulting paired reads were trimmed of 
B blocks in the quality scores from the end of the read. 
Trimmed reads shorter than 36 base pairs were removed. 
Reads were aligned using the Burrows-Wheeler Aligner 
version 0.6.2 [39] against the human genome GRCh37 
reference-genome primary assembly. Reads mapping to 
multiple genomic positions were removed. The alignment 
was refined using GATK Indel Realignment version 
3.4. After the alignment, potential PCR duplicates were 
removed with Picard MarkDuplicates version 1.90.
Somatic mutation analysis
Non-synonymous somatic mutations (missense, 
nonsense, frameshift, in-frame coding deletion/insertion 
and splice site mutations) were identified from the paired 
normal and tumor data using the VarScan 2 mutation 
detection algorithm version 2.3.2 [40]. The following 
parameters were used for calling high-confidence somatic 
mutations: strand-filter 1, min-coverage-normal 8, min-
coverage-tumor 6, somatic-p-value 1, normal-purity 1, 
and min-var-freq 0.05. Mutations were annotated using 
SnpEff version 4.0 [41] with the Ensembl v68 annotation 
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database [42]. To filter out misclassified germline variants, 
the common population variants included in the Database 
of Single Nucleotide Polymorphisms (dbSNP; https://
www.ncbi.nlm.nih.gov/snp) were removed. Variants with 
VarScan somatic p-value below 0.01 were selected for 
subsequent analyses.
Throughout this paper, the term “mutation” is 
used for any non-synonymous sequence change with 
the possibility of being pathogenic (including traditional 
pathogenicity classes 3 -5).
Second hit analysis of DNA mismatch repair 
(MMR) genes
LOH analyses took advantage of the predisposing 
mutation. When the predisposing mutation was a point 
mutation, LOH analysis was performed utilizing VCP 
filtered sequencing data (.vcf-files) on the predisposing 
MMR gene mutation regions obtained from tumor and 
normal samples by VarSeq (GoldenHelix®). The ratio of 
variant allele (Alt) to reference allele (Ref) reads was 
determined in tumor (T) and matching normal (N) DNA 
and the LOH ratio calculated using the following formula: 
R = (Alt:Ref)T/(Alt:Ref)N. The thresholds for LOH and 
putative LOH are specified in Ollikainen et al. [43] When 
the predisposing MMR mutation was a large deletion, 
LOH analysis was performed by MLPA (with SALSA 
P003-C1 for MLH1 and MSH2 and 072-C1 for MSH6, 
MRC Holland, Amsterdam, The Netherlands), and the 
results interpreted according to Zhang et al. [44].
Data on somatic point mutations in MLH1, MSH2, 
and MSH6 were obtained as part of the Nimblegen 
Comprehensive Cancer Panel. The promoters of MLH1, 
MSH2, and MSH6 were investigated for methylation by 
MS-MLPA as described in Valo et al. [8] and Niskakoski 
et al. [7].
In silico evaluation of somatic mutations for 
pathogenicity
In silico evaluation of somatic single nucleotide 
variants (SNVs) was conducted using VarSeq 
(GoldenHelix®) (Supplementary Tables 1 and 5). VarSeq 
includes 6 individual algorithms to predict the effect of 
amino acid substitution on protein function: SIFT (http://
sift.jcvi.org/), PolyPhen-2 [45], MutationTaster [46], 
MutationAssessor (http://mutationassessor.org/r3/), 
FATHMM [47–49], and FATHMM MKL Coding (http://
fathmm.biocompute.org.uk/). In the second hit analysis 
(Supplementary Table 1), splicing consequences of SNVs 
in splice site regions were predicted using Human Splicing 
Finder (http://www.umd.be/HSF3/). Somatic mutations in 
MMR genes were checked against the InSIGHT database 
(Leiden Open Variation Database, LOVD v. 2.0 Build 36; 
http://chromium.lovd.nl/LOVD2/colon_cancer/home.
php) for pathogenicity classifications (Supplementary 
Table 1). Somatic mutations in MMR genes as well as 
those affecting the top 72 colorectal tumor and 10 ovarian 
tumor-associated genes were also assessed for possible 
presence in the Catalogue of somatic mutations in cancer 
(COSMIC v71, GRCh 37; http://grch37-cancer.sanger.
ac.uk/cosmic) (Supplementary Tables 1 and 5).
Statistical analyses
Statistical analyses were conducted using the SPSS 
software, version 24.0 (IBM SPSS Inc., Chicago, IL, 
USA). The data were first checked for the applicability 
of parametric vs. non-parametric tests. Differences 
between the distributions of mutations or mutant genes 
in two independent groups were evaluated for statistical 
significance by the Mann-Whitney U test. The Fisher’s 
exact test was used for pairwise comparisons of frequency 
data. Correlations were assessed by determining the 
Pearson correlation coefficient for parametric data. Two-
tailed p-values < 0.05 were considered significant.
web resources
MRC Holland, http://mrc-holland.com.





Human Splicing Finder, http://www.umd.be/HSF3/.
InSIGHT database (Leiden Open Variation 
Database, LOVD v. 2.0 Build 36, http://chromium.lovd.
nl/LOVD2/colon_cancer/home.php.
Catalogue of somatic mutations in cancer 
(COSMIC), http://grch37-cancer.sanger.ac.uk/cosmic.
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